Literature DB >> 12369996

Structure-function relationships in chloroquine and related 4-aminoquinoline antimalarials.

T J Egan1.   

Abstract

Recent publication have provided strong evidence that activity and cellular uptake of 4-aminoquinoline antimalarials depends on vacuolar haemoglobin degradation and that haematin is the drug target. Studies on haematin-quinoline interactions have provided insight into the structural requirements for these interactions and indications are that 4-aminoquinolines may act by inhibiting haemozoin formation. Structural requirements for this activity have also been reported recently and have led to construction of an empirical structure-function relationship for 4-aminoquinolines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12369996     DOI: 10.2174/1389557013407188

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  14 in total

1.  A correlation study of quinoline derivatives and their pharmaceutical behavior by ab initio calculated NQR parameters.

Authors:  Marjan A Rafiee; Nasser L Hadipour; Hossein Naderi-manesh
Journal:  J Comput Aided Mol Des       Date:  2004-03       Impact factor: 3.686

2.  Synthesis and biological evaluation of 1,4-naphthoquinones and quinoline-5,8-diones as antimalarial and schistosomicidal agents.

Authors:  Don Antoine Lanfranchi; Elena Cesar-Rodo; Benoît Bertrand; Hsin-Hung Huang; Latasha Day; Laure Johann; Mourad Elhabiri; Katja Becker; David L Williams; Elisabeth Davioud-Charvet
Journal:  Org Biomol Chem       Date:  2012-07-10       Impact factor: 3.876

3.  N-cinnamoylated aminoquinolines as promising antileishmanial agents.

Authors:  S Vale-Costa; J Costa-Gouveia; B Pérez; T Silva; C Teixeira; P Gomes; M S Gomes
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

4.  Solution behavior of hematin under acidic conditions and implications for its interactions with chloroquine.

Authors:  Maria P Crespo; Leann Tilley; Nectarios Klonis
Journal:  J Biol Inorg Chem       Date:  2010-04-29       Impact factor: 3.358

Review 5.  Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.

Authors:  A M Mfuh; O V Larionov
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

6.  A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases().

Authors:  Bryan T Mott; Ken Chih-Chien Cheng; Rajarshi Guha; Valerie P Kommer; David L Williams; Jon J Vermeire; Michael Cappello; David J Maloney; Ganesha Rai; Ajit Jadhav; Anton Simeonov; James Inglese; Gary H Posner; Craig J Thomas
Journal:  Medchemcomm       Date:  2012-12       Impact factor: 3.597

7.  Antiplasmodial activity of [(aryl)arylsulfanylmethyl]Pyridine.

Authors:  Sanjay Kumar; Sajal Kumar Das; Sumanta Dey; Pallab Maity; Mithu Guha; Vinay Choubey; Gautam Panda; Uday Bandyopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2007-11-19       Impact factor: 5.191

8.  Chloroquine differentially modulates coronary vasodilation in control and diabetic mice.

Authors:  Qian Zhang; Atsumi Tsuji-Hosokawa; Conor Willson; Makiko Watanabe; Rui Si; Ning Lai; Ziyi Wang; Jason X-J Yuan; Jian Wang; Ayako Makino
Journal:  Br J Pharmacol       Date:  2020-01-08       Impact factor: 8.739

9.  Plasmodium falciparum exposure in utero, maternal age and parity influence the innate activation of foetal antigen presenting cells.

Authors:  Nadine Fievet; Stefania Varani; Samad Ibitokou; Valérie Briand; Stéphanie Louis; René Xavier Perrin; Achille Massougbogji; Anne Hosmalin; Marita Troye-Blomberg; Philippe Deloron
Journal:  Malar J       Date:  2009-11-05       Impact factor: 2.979

10.  Pharmacological Assessment of the Antiprotozoal Activity, Cytotoxicity and Genotoxicity of Medicinal Plants Used in the Treatment of Malaria in the Greater Mpigi Region in Uganda.

Authors:  Fabien Schultz; Ogechi Favour Osuji; Anh Nguyen; Godwin Anywar; John R Scheel; Guy Caljon; Luc Pieters; Leif-Alexander Garbe
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.